Literature DB >> 9658366

Are all type I human interferons equivalent?

G R Foster1, N B Finter.   

Abstract

The Type I interferons are a family of closely related cytokines that have antiviral and immunostimulatory properties. There has been prolonged debate regarding the different interferon-alpha subtypes: with some authorities suggest that the different interferons have essentially similar properties but others argue that there are significant differences between them. Recent work has shown that the various interferon-alpha subtypes can interact with the interferon receptor components in different ways and can activate a number of different signalling pathways. Recent studies on the immunomodulatory properties of the Type I interferons indicate that there are profound differences between the subtypes. The clinical significance of all these differences remains to be determined.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9658366     DOI: 10.1046/j.1365-2893.1998.00103.x

Source DB:  PubMed          Journal:  J Viral Hepat        ISSN: 1352-0504            Impact factor:   3.728


  25 in total

Review 1.  Interferon-zeta/limitin: novel type I interferon that displays a narrow range of biological activity.

Authors:  Kenji Oritani; Yoshiaki Tomiyama
Journal:  Int J Hematol       Date:  2004-11       Impact factor: 2.490

2.  Aicardi-Goutières syndrome displays genetic heterogeneity with one locus (AGS1) on chromosome 3p21.

Authors:  Y J Crow; A P Jackson; E Roberts; E van Beusekom; P Barth; P Corry; C D Ferrie; B C Hamel; R Jayatunga; G Karbani; R Kálmánchey; A Kelemen; M King; R Kumar; J Livingstone; R Massey; R McWilliam; A Meager; C Rittey; J B Stephenson; J L Tolmie; A Verrips; T Voit; H van Bokhoven; H G Brunner; C G Woods
Journal:  Am J Hum Genet       Date:  2000-05-25       Impact factor: 11.025

3.  Interferon-alpha2a is sufficient for promoting dendritic cell immunogenicity.

Authors:  A Tamir; W J Jordan; M Ritter; N Habib; R I Lechler; G R Foster; G Lombardi
Journal:  Clin Exp Immunol       Date:  2005-12       Impact factor: 4.330

4.  Total chemical synthesis of human interferon alpha-2b via native chemical ligation.

Authors:  Jing Li; Clara Lehmann; Xishan Chen; Fabio Romerio; Wuyuan Lu
Journal:  J Pept Sci       Date:  2015-03-24       Impact factor: 1.905

5.  The early interferon alpha subtype response in infant macaques infected orally with SIV.

Authors:  Juliet Easlick; Richard Szubin; Samantha Lantz; Nicole Baumgarth; Kristina Abel
Journal:  J Acquir Immune Defic Syndr       Date:  2010-09       Impact factor: 3.731

6.  Learning from viruses: the necrotic bodies of tumor cells with intracellular synthetic dsRNA induced strong anti-tumor immune responses.

Authors:  Zhengrong Cui; Uyen M Le; Fu Qiu; Dalia S Shaker
Journal:  Pharm Res       Date:  2007-04-03       Impact factor: 4.200

7.  Type I interferon gene therapy protects against cytomegalovirus-induced myocarditis.

Authors:  Vanessa S Cull; Emmalene J Bartlett; Cassandra M James
Journal:  Immunology       Date:  2002-07       Impact factor: 7.397

8.  The relationship between simian immunodeficiency virus RNA levels and the mRNA levels of alpha/beta interferons (IFN-alpha/beta) and IFN-alpha/beta-inducible Mx in lymphoid tissues of rhesus macaques during acute and chronic infection.

Authors:  Kristina Abel; Michelle J Alegria-Hartman; Kristina Rothaeusler; Marta Marthas; Christopher J Miller
Journal:  J Virol       Date:  2002-08       Impact factor: 5.103

9.  Vaccinia virus K1L and C7L inhibit antiviral activities induced by type I interferons.

Authors:  Xiangzhi Meng; Canhua Jiang; Janilyn Arsenio; Kevin Dick; Jingxin Cao; Yan Xiang
Journal:  J Virol       Date:  2009-08-05       Impact factor: 5.103

10.  Leukocyte interferon-alpha and ribavirin for treatment of chronic hepatitis C patients intolerant to pegylated-interferon.

Authors:  Luigi E Adinolfi; Emanuele Durante-Mangoni; Marta Salzillo; Aldo Marrone; Marie-Francoise Tripodi; Luciano Restivo; Antonietta Merola; Rosa Zampino; Giuseppe Ruggiero
Journal:  Intern Emerg Med       Date:  2009-12       Impact factor: 3.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.